In this episode of On The Line, host Matt Gurney is joined by two guests to discuss hockey, inflation, politics, and whether Canada can finally get serious about building major infrastructure. This episode is brought to you by BioCanRx. This month we’re addressing common questions, like: do these therapies have export potential? The farthest advanced BioCanRx-supported therapies are still in clinical trials here in Canada, but other countries are already expressing interest based on their efficacy and lower cost. Canadian-developed CAR-T technology from the CLIC group is already being used to treat clinical trial patients in Denmark, and other countries with high numbers of leukemia cases have expressed interest. A successful clinical trial in another country can be an important first step toward bringing that therapy to market there. If BioCanRx-supported therapies continue to be trialed outside Canada, it sends a strong signal that made-in-Canada immunotherapies will find a receptive
In the latest episode of The Line Podcast, recorded on November 13th, 2026, Matt Gurney is joined by Andrew Potter, filling in for Jen Gerson from Montreal. This episode is brought to you by Cameco. First up, your hosts tackle the immigration debate now exploding across Canada. Both are very mindful of the fact that they're middle-aged white dudes, but they have serious concerns about the government's new proposals. For one thing, the economic rationale simply isn't there. For another, the Liberals have done almost none of the political groundwork necessary to sell these changes to Canadians. As Andrew notes, this government, like most Liberal governments, hates having to explain itself to the public. Matt worries that the consequences could be severe. Canada has maintained a remarkable pro-immigrant consensus for decades, and while Canadians have clearly soured on immigration, they haven't yet soured on immigrants. That distinction matters. And it might not last. Next, Matt and Andrew
In this episode of On The Line, host Matt Gurney is joined by two guests to discuss what the federal budget tells us about Canada's plans for national defence, immigration, housing and the economy. This episode is brought to you by BioCanRx. This week we asked whether the new federal budget improves the landscape for Canadian drug development. Short answer: it does! New tax incentives will support Canadian biotech companies carrying out commercialization and regulatory activities in Canada, and federal research funding agencies will modernize to offer additional support for bridging lab to market. The government also pledged to respond to recommendations from last summer’s Pharmaceutical and Life Sciences Sector Task Force. Steps like these can address key challenges facing Canada's life-sciences sector and make Canada more globally competitive. There is much more work to do to support Canadian health-care systems. BioCanRx will continue to participate in any effort to strengthen Canad
In the latest episode of The Line Podcast, recorded between November 5th and 6th, 2026, Matt Gurney and Jen Gerson are joined by special guest Stephanie Levitz of The Globe and Mail. This episode is also brought to you by Cameco. First up, a brief explainer: due to Jen's being at a conference, part of this episode was recorded earlier in the week, after the midterms, but before the Canadian federal budget had been released. To avoid ignoring one of the huge stories of the week, Matt recorded a special segment of the podcast on Friday, after Jen had left for her event. In that segment, Stephanie Levitz joins Matt for a quick discussion of the federal budget. What's in it, what's missing, and what does it tell us about the Carney government's priorities? They take stock of what Ottawa is promising, what it's actually prepared to spend money on, and what Canadians should take away from it all. This episode is also brought to you by BioCanRx. This month we’re addressing common questions, l
In this episode of On The Line, host Jen Gerson speaks with Jeff Collins, director of the Palmer Institute for Canadian Leadership in Charlottetown, P.E.I., about Canada's military procurement problems, the country's evolving national security strategy, and whether our newfound enthusiasm for getting our elbows up against the Americans makes any sense when it comes to national defence. This episode is brought to you by BioCanRx. This month we’re addressing common questions, like: are immunotherapy technologies dual-use? While many immunotherapies are personalized using a patient’s own cells, the research and manufacturing infrastructure behind them can produce other important products, like vaccines. The people behind those research, manufacturing, and clinical delivery processes are also extremely capable and versatile. Greater support for translational research and clinical trials would help grow this workforce and build capabilities that extend well beyond cancer. In a health emerge